Research area

Immune & Inflammation protocols

Immune signaling, host defense, and inflammatory-response pathways under study.

Educational reference only. Peptides Made Clear does not provide medical advice, dosing recommendations or administration guidance. Values shown are what published sources or reviewed records report, never a suggestion for personal use.

Cinematic 3D visualization of immune cells signaling within tissue in teal and green light.

LL-37

LL-37, human cathelicidin antimicrobial peptide (hCAP18 C-terminal fragment)

Single peptideSource verified

Evidence: Early human research
Route: Topical application in the human wound studies. Intravenous and other systemic routes are not established.
Schedule: Topical wound studies applied the peptide on study-defined schedules. No systemic human schedule is established.
Vials: 5 mg, 10 mg

View protocol6 citations

Thymalin

Thymalin, a low-molecular-weight polypeptide complex extracted from calf thymus

Single peptideSource verified

Evidence: Human observational or case reports
Route: Intramuscular injection of a reconstituted lyophilisate, per Russian product labelling
Schedule: Russian product labelling describes daily intramuscular administration for short courses of roughly three to ten days, with courses sometimes repeated periodically.
Vials: 10 mg

View protocol6 citations

Thymosin Alpha-1

Thymosin alpha-1 (thymalfasin), a synthetic 28-amino-acid acetylated thymic peptide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection in essentially all approved use and trial protocols
Schedule: Chronic hepatitis regimens used twice-weekly subcutaneous administration over months. Sepsis trials used short courses of daily or twice-daily administration over five to seven days.
Vials: 1.6 mg, 5 mg, 10 mg

View protocol6 citations